Jing Xu

Publications (2)5.13 Total impact

• Article: CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies.

  Jing-Jun Wang, Yuan Zheng, Liang Sun, Li Wang, Peng-Bo Yu, Hong-Lei Li, Xiao-Ping Tian, Jian-Hua Dong, Lei Zhang, Jing Xu, Wei Shi, Tao-Yan Ma
  [show abstract] [hide abstract]
  ABSTRACT: Lung cancer is the second most common human malignant disease and the leading cause of cancer-related mortality worldwide. The effect of CYP1A1 IleVal polymorphism on susceptibility to lung cancer has been researched extensively over the last two decades. However, controversial results were obtained. To provide a more robust estimate of the effect, a meta-analysis was carried out. We systematically searched the PubMed database for studies published before August 2010, without language restriction. On the basis of our search criteria, a total of 32 studies (5126 patients and 6974 controls) were included in the meta-analysis. Overall, CYP1A1 IleVal polymorphism is associated with lung cancer risk (GG vs. AG+AA: odds ratio=1.61, 95% confidence interval: 1.19-2.17; GG vs. AA: odds ratio=1.70, 95% confidence interval: 1.23-2.35). Ethnic subgroup analyses showed that a significant association was found in Asians, but not in Africans, Caucasians, or other populations. In subgroup analyses by histology, the result is not reliable. In conclusion, this meta-analysis suggests that the CYP1A1 IleVal polymorphism might play a modest role in susceptibility to lung cancer, especially in Asians.
  European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP) 11/2011; 20(6):445-52. · 2.21 Impact Factor
• Article: TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis.

  Jing-Jun Wang, Yuan Zheng, Liang Sun, Li Wang, Peng-Bo Yu, Jian-Hua Dong, Lei Zhang, Jing Xu, Wei Shi, Yu-Chun Ren
  [show abstract] [hide abstract]
  ABSTRACT: Colorectal cancer constitutes a significant proportion of the global burden of cancer morbidity and mortality. A number of studies have been conducted to explore whether TP53 codon 72 polymorphism is associated with colorectal cancer susceptibility. However, controversial results were obtained. In order to derive a more precise estimation of the relationship, we systematically searched Medline, Google scholar, and Ovid database for studies reported before May 2010. A total of 3603 colorectal cancer cases and 5524 controls were included. TP53 codon 72 polymorphism was not associated with colorectal cancer risk in all genetic models (for dominant model: OR = 0.99, 95% CI: 0.86-1.15; for recessive model: OR = 1.00, 95% CI: 0.81-1.23; for Arg/Pro vs. Arg/Arg: OR = 1.00, 95% CI: 0.87-1.15; for Pro/Pro vs. Arg/Arg: OR = 0.97, 95% CI: 0.76-1.25). In the subgroup analyses by ethnic groups and sources of controls, no significant associations were found in all models. Taken together, this meta-analysis suggested that the biologically usefulness of TP53 codon 72 polymorphism as a selection marker in colorectal cancer susceptibility may be very limited.
  Molecular Biology Reports 12/2010; 38(8):4847-53. · 2.93 Impact Factor